Trial Profile
A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients With Severe (FVIII <1%) Hemophilia A
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BAX 826 (Primary) ; Octocog alfa
- Indications Haemophilia A
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Baxalta; Shire
- 14 Jan 2020 According to a Xenetic Biosciences media release, data from the study has been published in the journal Haemophilia.
- 22 May 2017 Results published in a Xenetic Biosciences media release.
- 18 Apr 2017 Status changed from recruiting to completed.